Lipid carriers for mRNA delivery.
10.1016/j.apsb.2022.11.026
- Author:
Wanting ZHANG
1
;
Yuxin JIANG
1
;
Yonglong HE
1
;
Hamza BOUCETTA
1
;
Jun WU
2
;
Zhongjian CHEN
3
;
Wei HE
3
Author Information
1. Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
2. Department of Geriatric Cardiology, Jiangsu Provincial Key Laboratory of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
3. Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
- Publication Type:Review
- Keywords:
COVID-19;
Drug delivery;
Encapsulation efficiency;
Endosome escape;
Lipid carriers;
Nanoparticles;
Vaccine;
mRNA
- From:
Acta Pharmaceutica Sinica B
2023;13(10):4105-4126
- CountryChina
- Language:English
-
Abstract:
Messenger RNA (mRNA) is the template for protein biosynthesis and is emerging as an essential active molecule to combat various diseases, including viral infection and cancer. Especially, mRNA-based vaccines, as a new type of vaccine, have played a leading role in fighting against the current global pandemic of COVID-19. However, the inherent drawbacks, including large size, negative charge, and instability, hinder its use as a therapeutic agent. Lipid carriers are distinguishable and promising vehicles for mRNA delivery, owning the capacity to encapsulate and deliver negatively charged drugs to the targeted tissues and release cargoes at the desired time. Here, we first summarized the structure and properties of different lipid carriers, such as liposomes, liposome-like nanoparticles, solid lipid nanoparticles, lipid-polymer hybrid nanoparticles, nanoemulsions, exosomes and lipoprotein particles, and their applications in delivering mRNA. Then, the development of lipid-based formulations as vaccine delivery systems was discussed and highlighted. Recent advancements in the mRNA vaccine of COVID-19 were emphasized. Finally, we described our future vision and perspectives in this field.
